The Breathlessness, Cough, and Sputum Scale - The development of empirically based guidelines for interpretation

被引:89
作者
Leidy, NK
Rennard, SI
Schmier, J
Jones, MKC
Goldman, M
机构
[1] MEDTAP Int Inc, Ctr Hlth Outcomes Res, Bethesda, MD 20814 USA
[2] Univ Nebraska, Med Ctr, Omaha, NE 68182 USA
[3] AstraZeneca, Wilmington, DE USA
关键词
bronchitis; clinical trials; COPD; cough; dyspnea; emphysema; exacerbation; health-related quality of life; instrument; patient-reported outcome; sputum; St. George Respiratory Questionnaire; symptoms;
D O I
10.1378/chest.124.6.2182
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Background: A patient report of respiratory symptoms in COPD is essential to successfully monitoring disease, adjusting treatment, and evaluating outcomes. Objective: To develop empirically based guidelines for interpreting mean changes in symptom scores using the Breathlessness, Cough, and Sputum Scale (BCSS). Methods: Analyses were performed on data from three multinational trials (n = 2,971). Mean changes in BCSS score with treatment were examined by physician and patient ratings of treatment efficacy, juxtaposed with percentage change in symptoms, statistical effect size (ES), DeltaFEV(1), and change in St. George Respiratory Questionnaire (SGRQ) score. BCSS scores during an exacerbation were examined relative to changes in peak expiratory flow and rescue medication use. Results: Mean baseline BCSS total score was 5.2 +/- 2 (+/- SD); 90% of scores were between 2 and 9. Highly efficacious treatment (n = 257; physician rating) was associated with a DeltaBCSS total score of - 1.3 +/- 1.8, representing a 24% improvement (ES = 0.7), and corresponding to a 10% improvement in FEV1, and DeltaSGRQ score total of - 10.3 +/- 13.8. Similar changes in BCSS score were observed during recovery from an exacerbation (n 713; - 1.3 +/- 1.8). Mean change with moderately efficacious treatment (n = 965) was - 0.7 +/- 1.8, a 13% improvement (ES = 0.3) corresponding to DeltaSGRQ total score of - 6.8 +/- 12.6. Mildly efficacious treatment (n = 891) was associated with a change of 0.35, a 7% improvement (ES = 0. 18), with a DeltaFEV(1) <1% and DeltaSGRQ total score of - 2.6 +/- 11.7. Conclusions: Patient-reported daily symptom data are sensitive to change and useful for both observational studies and controlled clinical trials of patients with COPD. A mean DeltaBCSS total score > 1.0 represents substantial symptomatic improvement, changes of approximately 0.6 can he interpreted as moderate, and changes of 0.3 can be considered small.
引用
收藏
页码:2182 / 2191
页数:10
相关论文
共 26 条
[1]   PSYCHOPHYSICAL BASES OF PERCEIVED EXERTION [J].
BORG, GAV .
MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 1982, 14 (05) :377-381
[2]   Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial [J].
Burge, PS ;
Calverley, PMA ;
Jones, PW ;
Spencer, S ;
Anderson, JA ;
Maslen, TK .
BMJ-BRITISH MEDICAL JOURNAL, 2000, 320 (7245) :1297-1303
[3]   A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease [J].
Casaburi, R ;
Mahler, DA ;
Jones, PW ;
Wanner, A ;
San Pedro, G ;
ZuWallack, RL ;
Menjoge, SS ;
Serby, CW ;
Witek, T .
EUROPEAN RESPIRATORY JOURNAL, 2002, 19 (02) :217-224
[4]   Symptoms are an important outcome in chronic obstructive pulmonary disease clinical trials: results of a 3-month comparative study using the Breathlessness, Cough and Sputum Scale (BCSS) [J].
Celli, B ;
Halpin, D ;
Hepburn, R ;
Byrne, N ;
Keating, ET ;
Goldman, M .
RESPIRATORY MEDICINE, 2003, 97 :S35-S43
[5]  
CELLI BR, 1995, AM J RESP CRIT CARE, V152, pS77
[6]  
Cohen J., 1998, Statistical Power Analysis for the Behavioral Sciences, V2nd
[7]   Relationship between chronic dyspnea and expiratory flow limitation in patients with chronic obstructive pulmonary disease [J].
Eltayara, L ;
Becklake, MR ;
Volta, CA ;
MilicEmili, J .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (06) :1726-1734
[8]   A MEASURE OF QUALITY-OF-LIFE FOR CLINICAL-TRIALS IN CHRONIC LUNG-DISEASE [J].
GUYATT, GH ;
BERMAN, LB ;
TOWNSEND, M ;
PUGSLEY, SO ;
CHAMBERS, LW .
THORAX, 1987, 42 (10) :773-778
[9]   A SELF-COMPLETE MEASURE OF HEALTH-STATUS FOR CHRONIC AIR-FLOW LIMITATION - THE ST-GEORGES RESPIRATORY QUESTIONNAIRE [J].
JONES, PW ;
QUIRK, FH ;
BAVEYSTOCK, CM ;
LITTLEJOHNS, P .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1992, 145 (06) :1321-1327
[10]   Quality of life changes in COPD patients treated with salmeterol [J].
Jones, PW ;
Bosh, TK .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1997, 155 (04) :1283-1289